Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose
 ductal carcinoma in situ.

 PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for
 pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and
 atypical ductal hyperplasia, a risk factor for developing cancer.
OBJECTIVES:

 -  Compare the DCIS optimized MRI to the standard clinical MRI. Using a scale of 1-5 from
 poor to excellent, images will be assessed for conspicuity of DCIS and atypical ductal
 hyperplasia (ADH) lesions, agreement of disease extent with biopsy, and overall image
 quality (artifact level, uniformity of fat suppression, contrast to noise ratio and
 signal to noise ratio).

 -  Subjects with ADH, a benign condition that can also show enhancement on MRI, will be
 enrolled to explore the utility of the DCIS optimized MRI for distinguishing DCIS and
 ADH.
DISEASE CHARACTERISTICS:

 -  Meets 1 of the following criteria:

 -  Patient at the University of California, San Francisco Breast Care Center meeting
 the following criteria:

 -  Biopsy proven ductal carcinoma in situ (DCIS) of the breast.

 -  Has undergone mammography within the past 60 days.

 -  ADH patients: over 18, no prior history of breast disease.

 PATIENT CHARACTERISTICS:

 -  Not pregnant or nursing (or stopped nursing within the past 3 months)

 -  Negative pregnancy test

 -  No contraindication to MRI (e.g., implanted pacemaker, implanted ferromagnetic device,
 ferromagnetic aneurysm clip, severe claustrophobia, ocular metal fragments, or
 shrapnel injury)

 PRIOR CONCURRENT THERAPY:

 -  More than 2 years since prior surgery to the ipsilateral breast (patient)

 -  No prior radiotherapy to the ipsilateral breast (patient)

 -  No prior cytotoxic regimens (patient)